|1.||Kivikko, Matti: 3 articles (04/2008 - 04/2004)|
|2.||Pentikäinen, Pertti J: 3 articles (04/2008 - 04/2004)|
|3.||Häkkinen, Sari: 2 articles (04/2008 - 01/2007)|
|4.||Puttonen, Jaakko: 2 articles (04/2008 - 01/2007)|
|5.||Kantele, Sampo: 2 articles (04/2008 - 01/2007)|
|6.||Antila, Saila: 2 articles (01/2007 - 04/2004)|
|7.||Louhelainen, Marjut: 1 article (05/2010)|
|8.||Finckenberg, Piet: 1 article (05/2010)|
|9.||Levijoki, Jouko: 1 article (05/2010)|
|10.||Merasto, Saara: 1 article (05/2010)|
05/01/2010 - "Effects of oral OR-1896 treatment on post-infarct heart failure and cardiac remodelling were assessed in diabetic Goto-Kakizaki (GK) rats, an animal model of type II diabetes. "
01/01/2007 - "The long-acting haemodynamic responses reflect levels of the active metabolites OR-1896 and OR-1855, maximal metabolite levels occurred at day 3. Levosimendan infusion achieved a rapid improvement in haemodynamic parameters in patients with congestive heart failure with maximal effects occurring 1-3 days after starting the infusion, effects were sustained for up to at least a week."
05/01/2007 - "Levosimendan also seems to induce a prolonged haemodynamic improvement in patients with heart failure as a result of the long half-life of its active metabolite, OR-1896. "
04/01/2004 - "The purpose of the study was to characterize the pharmacokinetics of levosimendan and its metabolites OR-1855 and OR-1896 in patients with congestive heart failure. "
05/01/2010 - "Oral treatment with calcium sensitizer OR-1896 protects against post-infarct heart failure and cardiac remodelling in experimental model of type II diabetes."
|2.||Cardiomegaly (Heart Hypertrophy)
09/01/2009 - "OR-1896 prevented salt-induced cardiovascular mortality (survival rate 75 % in OR-1896 treated groups vs 38 % in untreated controls, p<0.01), ameliorated cardiac hypertrophy and improved systolic functions of the heart without major influence on systemic blood pressure. "
05/01/2010 - "OR-1896 ameliorated post-infarct cardiac hypertrophy, and prevented the MI-induced increase in cardiac mRNA for atrial natriuretic peptide, monocyte chemoattractant protein-1 and connective tissue growth factor, markers of pressure/volume overload, inflammation and fibrosis respectively. "
|3.||Alcoholic Liver Cirrhosis (Alcoholic Cirrhosis)
04/01/2008 - "In the present study, the effect of hepatic impairment on the pharmacokinetics of levosimendan and its 2 metabolites, OR-1855 and OR-1896 (pharmacologically active), was investigated in 12 healthy subjects and 12 subjects with moderate hepatic impairment due to alcoholic cirrhosis of the liver but with no heart failure. "
|4.||Hypertension (High Blood Pressure)
09/01/2009 - "Our findings suggest a therapeutic role for OR-1896 in the prevention of cardiac remodelling in salt-sensitive forms of hypertension. "
09/01/2009 - "In the present study we tested the hypothesis whether OR-1896, an active and long-lasting metabolite of calcium sensitizer levosimendan, prevents cardiovascular mortality and hypertension-induced myocardial remodelling in salt-sensitive Dahl/Rapp rats. "
|2.||N- (4- (4- methyl- 6- oxo- 1,4,5,6- tetrahydropyridazin- 3- yl)phenyl)acetamide (OR 1896)
|4.||Connective Tissue Growth Factor
|5.||Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
|6.||Messenger RNA (mRNA)
|7.||Blood Glucose (Blood Sugar)